Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 15:355:i5813.
doi: 10.1136/bmj.i5813.

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study

Affiliations

Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study

Fatmah Othman et al. BMJ. .

Abstract

Objective To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association.Design Cohort study and self controlled case series.Setting Clinical Practice Research Datalink (1990 to 2013) in UK.Participants Adult patients with a new prescription for a PPI individually matched with controls.Main outcome measures Association of community acquired pneumonia with PPI prescription estimated by three methods: a multivariable Cox model comparing risk in PPI exposed patients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPI prescription.Results 160 000 new PPI users were examined. The adjusted Cox regression showed a risk of community acquired pneumonia 1.67 (95% confidence interval 1.55 to 1.79) times higher for patients exposed to PPI than for controls. In the self controlled case series, among 48 451 PPI exposed patients with a record of community acquired pneumonia, the incidence rate ratio was 1.19 (95% confidence interval 1.14 to 1.25) in the 30 days after PPI prescription but was higher in the 30 days before a PPI prescription (1.92, 1.84 to 2.00). The Cox regressions for prior event rate ratio similarly showed a greater increase in community acquired pneumonia in the year before than the year after PPI prescription, such that the analysis showed a reduced relative risk of pneumonia associated with PPI use (prior event rate ratio 0.91, 95% confidence interval 0.83 to 0.99).Conclusion The association between the use of PPIs and risk of community acquired pneumonia is likely to be due entirely to confounding factors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: FO has received a scholarship award from King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia, which sponsors her studies at the University of Nottingham; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work .

Figures

None
Fig 1 Illustration of self controlled case series method showing division of time of each person included in this analysis to assess incidence of community acquired pneumonia in relation to prescription for proton pump inhibitor (PPI). Events of pneumonia can occur during baseline or exposure period
None
Fig 2 Prior event rate ratio adjustment method. Prior period means time before index date (proton pump inhibitor (PPI) prescription date for exposed cohort and matched date for unexposed patients); post period means time after PPI exposure

Comment in

Similar articles

Cited by

References

    1. Mazer-Amirshahi M, Mullins PM, van den Anker J, Meltzer A, Pines JM. Rising rates of proton pump inhibitor prescribing in US emergency departments. Am J Emerg Med 2014;32:618-22. 10.1016/j.ajem.2014.03.019 pmid:24721025. - DOI - PubMed
    1. Cahir C, Fahey T, Tilson L, Teljeur C, Bennett K. Proton pump inhibitors: potential cost reductions by applying prescribing guidelines. BMC Health Serv Res 2012;12:408 10.1186/1472-6963-12-408 pmid:23163956. - DOI - PMC - PubMed
    1. Heidelbaugh JJ, Goldberg KLIJ. Adverse risks associated with proton pump inhibitors: a systematic review. Gastroenterol Hepatol 2009;5:725-34. - PMC - PubMed
    1. Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?World J Gastrointest Pharmacol Ther 2011;2:17-26. 10.4292/wjgpt.v2.i3.17 pmid:21731913. - DOI - PMC - PubMed
    1. Eom C-S, Jeon CY, Lim J-W, Cho E-G, Park SM, Lee K-S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011;183:310-9. 10.1503/cmaj.092129 pmid:21173070. - DOI - PMC - PubMed

Substances